Literature DB >> 34743789

Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.

Kiran Maski1, Lynn Marie Trotti2, Suresh Kotagal3, R Robert Auger4, James A Rowley5, Sarah D Hashmi6, Nathaniel F Watson7.   

Abstract

INTRODUCTION: This guideline establishes clinical practice recommendations for the treatment of central disorders of hypersomnolence in adults and children.
METHODS: The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to each recommendation, based on a systematic review of the literature and an assessment of the evidence using the GRADE process. The task force provided a summary of the relevant literature and the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. RECOMMENDATIONS: The following recommendations are intended to guide clinicians in choosing a specific treatment for central disorders of hypersomnolence in adults and children. Each recommendation statement is assigned a strength ("strong" or "conditional"). A "strong" recommendation (ie, "We recommend…") is one that clinicians should follow under most circumstances. A "conditional" recommendation (ie, "We suggest…") is one that requires that the clinician use clinical knowledge and experience and strongly consider the individual patient's values and preferences to determine the best course of action. Under each disorder, strong recommendations are listed in alphabetical order followed by the conditional recommendations in alphabetical order. The section on adult patients with hypersomnia because of medical conditions is categorized based on the clinical and pathological subtypes identified in ICSD-3. The interventions in all the recommendation statements were compared to no treatment. 1: We recommend that clinicians use modafinil for the treatment of narcolepsy in adults. (STRONG). 2: We recommend that clinicians use pitolisant for the treatment of narcolepsy in adults. (STRONG). 3: We recommend that clinicians use sodium oxybate for the treatment of narcolepsy in adults. (STRONG). 4: We recommend that clinicians use solriamfetol for the treatment of narcolepsy in adults. (STRONG). 5: We suggest that clinicians use armodafinil for the treatment of narcolepsy in adults. (CONDITIONAL). 6: We suggest that clinicians use dextroamphetamine for the treatment of narcolepsy in adults. (CONDITIONAL). 7: We suggest that clinicians use methylphenidate for the treatment of narcolepsy in adults. (CONDITIONAL). 8: We recommend that clinicians use modafinil for the treatment of idiopathic hypersomnia in adults. (STRONG). 9: We suggest that clinicians use clarithromycin for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 10: We suggest that clinicians use methylphenidate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 11: We suggest that clinicians use pitolisant for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 12: We suggest that clinicians use sodium oxybate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 13: We suggest that clinicians use lithium for the treatment of Kleine-Levin syndrome in adults. (CONDITIONAL). 14: We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to dementia with Lewy bodies in adults. (CONDITIONAL). 15: We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to Parkinson's disease in adults. (CONDITIONAL). 16: We suggest that clinicians use sodium oxybate for the treatment of hypersomnia secondary to Parkinson's disease in adults. (CONDITIONAL). 17: We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL). 18: We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL). 19: We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to myotonic dystrophy in adults. (CONDITIONAL). 20: We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to multiple sclerosis in adults. (CONDITIONAL). 21: We suggest that clinicians use modafinil for the treatment of narcolepsy in pediatric patients. (CONDITIONAL). 22: We suggest that clinicians use sodium oxybate for the treatment of narcolepsy in pediatric patients. (CONDITIONAL). CITATION: Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.
© 2021 American Academy of Sleep Medicine.

Entities:  

Keywords:  Kleine-Levin syndrome; Parkinson’s disease; dementia with lewy bodies; hypersomnia; idiopathic hypersomnia; multiple sclerosis; myotonic dystrophy; narcolepsy; traumatic brain injury; treatment

Mesh:

Substances:

Year:  2021        PMID: 34743789      PMCID: PMC8636351          DOI: 10.5664/jcsm.9328

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.324


  5 in total

1.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

Authors:  Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-31       Impact factor: 6.437

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  The Evolution of the AASM Clinical Practice Guidelines: Another Step Forward.

Authors:  Timothy I Morgenthaler; Ludmila Deriy; Jonathan L Heald; Sherene M Thomas
Journal:  J Clin Sleep Med       Date:  2016-01       Impact factor: 4.062

4.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; Todd J Swick; James A Rowley; Sarah D Hashmi; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

Review 5.  Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Timothy I Morgenthaler; Vishesh K Kapur; Terry Brown; Todd J Swick; Cathy Alessi; R Nisha Aurora; Brian Boehlecke; Andrew L Chesson; Leah Friedman; Rama Maganti; Judith Owens; Jeffrey Pancer; Rochelle Zak
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

  5 in total
  12 in total

1.  Idiopathic Hypersomnia-A Dynamic Simulation Model.

Authors:  Marek Susta; Karel Šonka; Gustav Bizik; Svojmil Petranek; Sona Nevsimalova
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

2.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; Todd J Swick; James A Rowley; Sarah D Hashmi; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

3.  Emerging Treatments for Disorders of Consciousness in Paediatric Age.

Authors:  Hassna Irzan; Marco Pozzi; Nino Chikhladze; Serghei Cebanu; Artashes Tadevosyan; Cornelia Calcii; Alexander Tsiskaridze; Andrew Melbourne; Sandra Strazzer; Marc Modat; Erika Molteni
Journal:  Brain Sci       Date:  2022-01-31

4.  Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

Authors:  Young-A Heo
Journal:  CNS Drugs       Date:  2022-03-31       Impact factor: 6.497

5.  Medications for daytime sleepiness in individuals with idiopathic hypersomnia.

Authors:  Lynn M Trotti; Lorne A Becker; Catherine Friederich Murray; Romy Hoque
Journal:  Cochrane Database Syst Rev       Date:  2021-05-25

6.  Idiopathic hypersomnia: does first to approval mean first-line treatment?

Authors:  Lynn Marie Trotti
Journal:  Lancet Neurol       Date:  2022-01       Impact factor: 59.935

Review 7.  Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy.

Authors:  Yves Dauvilliers; Richard K Bogan; Karel Šonka; Markku Partinen; Nancy Foldvary-Schaefer; Michael J Thorpy
Journal:  Nat Sci Sleep       Date:  2022-03-29

8.  Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.

Authors:  Thomas Roth; Yves Dauvilliers; Michael J Thorpy; Clete Kushida; Bruce C Corser; Richard Bogan; Russell Rosenberg; Jordan Dubow; David Seiden
Journal:  CNS Drugs       Date:  2022-04-05       Impact factor: 5.749

Review 9.  Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update.

Authors:  Andrea Romigi; Tiziana Feola; Simone Cappellano; Michelangelo De Angelis; Giacomo Pio; Marco Caccamo; Federica Testa; Giuseppe Vitrani; Diego Centonze; Claudio Colonnese; Vincenzo Esposito; Marie-Lise Jaffrain-Rea
Journal:  Front Neurol       Date:  2022-02-09       Impact factor: 4.003

10.  Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy.

Authors:  Jordan Dubow; Alon Y Avidan; Bruce Corser; Amod Athavale; David Seiden; Clete Kushida
Journal:  Patient Prefer Adherence       Date:  2022-04-07       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.